

























The Space Radiation Problem
• Interplanetary crews will be exposed to a 
high LET radiation  environment comprised 
of high-energy protons and heavy ions 
(HZE’s)  as well as secondary protons, 
neutrons, and fragments produced in 
shielding and tissue
• Heavy ions are qualitatively different from X-
rays or Gamma-rays: High LET vs. low LET
− Densely ionizing along particle track
− Cause unique damage to biomolecules, 
cells, and tissues
− Distinct patterns of DNA damage 
(mutation spectra, chromosome 
aberrations) and distinct profiles of 
oxidative damage
• No human data  exist to estimate risk from 
heavy ions found in space
– Animal and cellular models with 
simulated space radiation must be 
applied or developed












High LET defined as




Risk of Radiation Carcinogenesis
• Morbidity and mortality risks; major driver for PELs
Risk of Acute (in flight)  & Late Central Nervous System Effects
• Possible in-flight risks: altered cognitive function including short-term 
memory, reduced motor function, and behavioral changes which may 
affect performance and human health 
• Possible late (post-mission) risks: neurological disorders such as 
Alzheimer’s disease (AD), dementia, cerebrovascular disease or 
premature aging
Risk of Cardiovascular Disease and other Degenerative Tissue 
Effects
• Degenerative changes in the heart, vasculature, and lens
• Diseases related to aging, including digestive, respiratory disease, 
premature senescence, endocrine, and immune system dysfunction
Risk of Acute Radiation Syndromes due to Solar Particle Events
• Prodromal effects (nausea, vomiting, anorexia, and fatigue), skin injury, 
































































10Shimizu 2010 ‐ BMJ ‐ Radiation exposure and circulatory disease risk‐ Hiroshima and Nagasaki atomic bomb survivor data, 1950‐2003
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• Recent studies of atomic bomb survivor data and analyses of epidemiology data from occupational and 
medical exposures provide evidence for elevation of risk at lower doses than previously identified, with 
significant risks at doses as low as 0.5 Gy
‒ Data at low doses is confounded by life-style factors, clouding interpretation of epidemiology 
data below 0.5 Gy
‒ Effects are considered deterministic, with an associated threshold dose; however recent 
evidence showing risk at lower doses questions this assumption
• Preliminary risk assessment models are being formulated based on recent epidemiology data for lower 
dose low-LET exposures - future risk estimates dependent on research results describing the 
quantitative and qualitative differences between GCR and gamma-rays
– Studies at NSRL with HZE ions and appropriate animals models are required
– Lack of evidence on radiation quality, disease spectrum, latency and dose rate at low levels 
of exposures
• The additional mortality and morbidity risks for non-cancer diseases of the cardiovascular 
system are major concerns because they could increase REID values substantially
• Association between exposure to high doses of low-LET (>5 
Gy) radiation during radiotherapy to the chest and 
increased risk for development of cardiovascular disease at 







































Degen ‐ 4: How does individual susceptibility including hereditary pre‐disposition alter degenerative 
tissue risks? Does individual susceptibility modify possible threshold doses for these risks in a 
significant way?
Degen ‐ 5: What quantitative procedures or theoretical models are needed to extrapolate molecular, 
cellular, or animal results to predict degenerative tissue risks in astronauts? How can human 
epidemiology data best support these procedures or models?
Degen ‐ 6: What are the most effective biomedical or dietary countermeasures to degenerative 
tissue risks? By what mechanisms are the countermeasures likely to work? Are these CMs 
additive, synergistic, or antagonistic to other Risks?
Degen ‐ 7: Are their significant synergistic effects from other spaceflight factors (microgravity, stress, 
altered circadian rhythms, changes in immune responses, etc.) that modify the degenerative risk 
from space radiation?
Degen ‐ 8: Are there research approaches using simulated space radiation that can elucidate the 
potential confounding effects of tobacco use on space radiation circulatory disease risk estimates?
31
Three Phase Implementation:
1. Phase 1: Develop biological models, investigate existence of dose thresholds for 
CVD effects, investigate mechanisms, define radiation quality effects and dose‐
rate effects
• Through individual NRAs and the NSBRI CSRR
2. Phase 2: Investigate latency periods, progression rates, and individual 
susceptibility effects
• Through individual NRAs and the NSCORs
3. Phase 3: Identify biomarkers and countermeasures for CVD and investigate 
potential synergies with other spaceflight factors.
• Through individual NRAs and a countermeasure NSCOR
Overall, there is a paucity of experimental data related to radiation‐
induced heart diseases at low doses:
 Qualitative differences between GCR and gamma‐rays are 
major concern
 Deterministic versus stochastic effects is unknown at doses 
<0.5 Gy. 
 Impact of dose rate
 A concern for Mars or lunar missions due to higher GCR and 
SPE doses with definitive effects 
 Recently established NSBRI Center for Space Radiation 
Research will focus on cardiovascular risk research
 Can cataract monitoring in astronauts provide insight into 
radiation quality effects, progression, and latency, specifically 
for space radiation exposure in humans?
 For relevant space radiation doses, can cataracts and kidney 
dysfunction be related to other radiation‐induced pathologies 
including CVD?
